港股異動丨百濟神州(6160.HK)大漲近12%破頂 股價站上200港元大關
格隆匯1月14日丨百濟神州(6160.HK)高開高走,現漲11.56%,盤中高見204港元創歷史新高價,股價首次站上200港元大關,市值達2400億港元。在12日公司正式對外宣佈,與全球頂尖製藥公司諾華攜手,就公司自主研發的PD-1藥物替雷利珠單抗(商品名:百澤安)達成全球戰略合作,共同推進該藥未來在多個國家的臨牀開發和商業化工作。據瞭解,此次合作總交易金額超22億美元,創下國內藥企單品種海外授權交易的全新紀錄。麥格理指出,百濟神州最有價值的競爭力仍然是其交易能力,看到其最近與Novartis Pharma(諾華)達成另一項具里程碑意義的交易,授權區域包括在大中華區、韓國、東盟和澳洲以外的主要地區。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.